EPICRISPR BIOTECHNOLOGIES CLOSES $90 MILLION OVERSUBSCRIBED SERIES C FINANCING TO ADVANCE FIRST-IN-CLASS EPIGENETIC THERAPY TOWARD PIVOTAL STUDIES IN FSHD

Reuters · 4d ago

Please log in to view news